Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
marketinference1d
Catalyst Pharmaceuticals Settles Patent Dispute
Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
bovnews2d
Analysts Predict a $35 Target for Catalyst Pharmaceuticals Inc (CPRX) Stock—What Could Drive It There?
Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...
Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...
Catalyst Pharma’s Strategic Positioning and Market Exclusivity Drive Buy Rating
In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Catalyst Pharma (CPRX – Research Report), ...
Catalyst stock climbs 15% on Firdapse litigation settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...